Anna JonebringSenior research scientist, iPSC/Primary cell/Stem Cell and Assay Development Team AstraZeneca
Rakesh K. JainDirector, Edwin L. Steele Laboratory of Tumor Biology Massachusetts General Hospital Cancer Center
Roberto IaconeGroup Head, Stem Cell, Cardiovascular & Metabolism Roche
Janet DavisScientific Director Janssen
Innovation has been sweeping across the stem cell field over the last 6-12 months. It’s clear that pharma and biotech leaders are making huge progress in differentiation, modeling, screening and predictive toxicology.
You’ve said that it’s through discussion and debate that the field can drive forward the practical utility of stem cell derived models.
The 3rd Stem Cells for Drug Developers meeting will bring together experts from AstraZeneca, Harvard Medical School, Novartis and many others who will help you tackle the key issues to develop, use and validate your stem cell derived models and assays.
So whether you’re developing assays for compound screening or working to improve differentiation protocols, the 3rd Stem Cells for Drug Developers is the place to learn, network and discuss how to achieve these goals.
There are a number of ways you can register:
Don't waste time! Get the best rates by securing your place now.
“Excellent overview of pharma’s interests and opportunities” Merck
“Nicely balanced cross sections of the current state of stem cell applications” Pfizer
“This was a great event to gain insight into the broad approaches of stem cells in the drug discovery space” Beckman Coulter
“Excellent depth of information on the topic” Aldagen
“Informative with fantastic networking opportunities, very well organised” Harvard University
“Excellent content” BD Technologies